LifeSpan BioSciences to release 20,000 immunohistochemistry-validated reagent antibodies
Leader in antibody evaluation and validation expands focus to include development and sales of antibodies validated for use in immunohistochemistry
"We have a tremendous opportunity to leverage our leadership position in antibody validation to become the dominant provider of high-quality antibodies to the research and pharmaceutical communities," said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president of LifeSpan. "This is a very exciting time for LifeSpan. Our experience providing IHC services to over 300 pharmaceutical and biotech companies for the past 12 years positions us as uniquely capable of identifying the best antibodies for future diagnostic and therapeutic applications."
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous